The National Centre for Research and Development grant TECHMATSTRATEG2/410747/11/NCBR/2019 (2019-2022) to the Consortium led by University of Gdansk in partnership with BioVentures Institute: „New generation bioactive molecules delivery systems, based on chemically synthesised and obtained through genetic engineering niematerializowany” is dedicated to the construction of several classes of novel bionanoparticles, including recombinant bacteriophages and Virus-Like-Particles (VLP) for biomedical applications. The short movie below introduces the Project, some Consortium team members and key leaders opinions. https://www.youtube.com/watch?v=aaIRFitlx5M&t=5s
The publication reviewing potential and used by BioVentures Institute thermophilic bacteriophages and Virus-Like-Particles (VLPs) ‘scaffolds’ for the development of novel nanobiotechnologies, suitable for fusion with concatemeric proteins, based on DNA-FACE™.
The vaccine has been purified, analysed using a number of techniques, including electrophoresis, LC-MS, Western blotting and was subjected to initial animal trials in rabbits. The anti-SARS-CoV-2 vaccine turned out to be non-toxic to all of the animals vaccinated. The Western blotting with the use of the rabbits antibodies was conducted using native Spike and Nucleoprotein proteins (purchased from an independent, foreign company), expressed in human cells, thus identical to those present in the virus, including posttranslational modification. Strong, specific immunological reaction was obtained, as shown in Figure 1. Currently, this novel type of anti-SARS-CoV-2 vaccine undergoes further full-scale evaluation, the regulated pre-clinical animal and in vitro tests.
Figure 1. Immunogenicity of the recombinant anti-SARS-CoV-2 vaccine as confirmed using vaccinated rabbit antibodies and Western blotting detection. Lane M, Page RulerTM Plus Prestained Protein Ladder (Thermo Scientific); lane 1, immunodetection of human cells-produced SARS-CoV-2 Spike protein; lane 2, immunodetection of human cells-produced SARS-CoV-2 Nucleocapsid protein.